In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

CV Therapeutics, Inc.

http://www.cvt.com

Latest From CV Therapeutics, Inc.

CinnaGen Reports Results Of ReciGen For COVID-19

CinnaGen has revealed clinical trial results suggesting that its ReciGen interferon beta-1a product in combination with concomitant antiviral therapy can be “a new safe and effective” treatment option for COVID-19 patients, “critical for the expected second wave of the pandemic.”

Clinical Trials Coronavirus COVID-19

Is Dexamethasone The Next Hydroxychloroquine For India?

While the jury is still out on dexamethasone being the new hero in the fight against COVID-19 after the hype around hydroxychloroquine has died down, Indian pharma is watching developments closely. Gains of companies like Zydus Cadila, Wockhardt, Cadila and Cipla in the domestic market will be constrained by price caps while any increase in exports will depend on emergency use authorizations.

Coronavirus COVID-19 India

Is Dexamethasone The Next HCQ For Indian Pharma?

While the jury is still out on dexamethasone being the new hero in the fight against COVID-19 after the hype around hydroxychloroquine has died down, Indian pharma is watching developments closely. Gains of companies like Zydus Cadila, Wockhardt, Cadila and Cipla in the domestic market will be constrained by price caps while any increase in exports will depend on emergency use authorizations

India Coronavirus COVID-19

Can Zydus Cadila's Cut-Price Enzalutamide Shake Up Indian Market?

Cadila Healthcare has launched a generic version of Astellas/Pfizer’s prostate cancer therapy Xtandi in India at a sharp discount of 70-90% to existing brands and hopes the lower financial burden on patients will aid adherence.

Commercial Business Strategies
See All

Company Information

UsernamePublicRestriction

Register